Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) insider Yuri Maricich acquired 6,551 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average cost of $1.65 per share, for a total transaction of $10,809.15. Following the completion of the acquisition, the insider owned 12,611 shares in the company, valued at $20,808.15. This represents a 108.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

CAMP4 Therapeutics Stock Performance

NASDAQ:CAMP traded down $0.15 during mid-day trading on Wednesday, reaching $4.01. The stock had a trading volume of 86,050 shares, compared to its average volume of 176,472. The stock has a market capitalization of $208.24 million, a P/E ratio of -1.70 and a beta of 0.22. The firm has a 50 day moving average price of $4.02 and a two-hundred day moving average price of $4.31. CAMP4 Therapeutics Corporation has a one year low of $1.32 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The business had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. Research analysts forecast that CAMP4 Therapeutics Corporation will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC increased its position in shares of CAMP4 Therapeutics by 35.9% in the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after acquiring an additional 1,666,666 shares during the period. Vivo Capital LLC boosted its holdings in shares of CAMP4 Therapeutics by 8.3% during the fourth quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock worth $26,031,000 after purchasing an additional 325,000 shares during the period. Balyasny Asset Management L.P. purchased a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $14,938,000. Adage Capital Partners GP L.L.C. grew its stake in shares of CAMP4 Therapeutics by 11.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider’s stock worth $13,374,000 after purchasing an additional 220,895 shares during the last quarter. Finally, SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics in the first quarter worth about $1,497,000.

Wall Street Analysts Forecast Growth

CAMP has been the topic of a number of analyst reports. Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective on the stock. Zacks Research downgraded CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.36.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.